Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 310 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overweight Subjects Clear all
Terminated Phase 2 Interventional Results available

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

NCT01351753
View directory record Official record
Conditions
Obesity, Metabolic Syndrome X
Interventions
Metformin, Orlistat, Topiramate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 9, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Metabolic Biomarkers in Varying Subjects

NCT01199692
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 9, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

LOSS- Louisiana Obese Subjects Study

NCT00115063
View directory record Official record
Conditions
Obesity
Interventions
group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition
Behavioral · Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 9, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

NCT00388180
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidaemias, Obesity
Interventions
GW501516, GW590735
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

NCT02311673
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 9, 2026, 5:22 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

BAriatric Surgery Induced Chromosomal Change

NCT05903521
View directory record Official record
Conditions
Obesity, Morbid
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

NCT00650806
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
35
States / cities
Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity

NCT03842501
View directory record Official record
Conditions
Obesity
Interventions
Release Supplement, Placebo
Dietary Supplement
Lead sponsor
Golo
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Valparaiso, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

NCT02398669
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

NCT05215418
View directory record Official record
Conditions
Blood Pressure
Interventions
VI-0521, Phentermine, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
28
States / cities
Anniston, Alabama • Mobile, Alabama • Lincoln, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 4 Interventional

A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.

NCT00234988
View directory record Official record
Conditions
Obesity
Interventions
sibutramine hydochloride monohydrate
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2008 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

NCT03661879
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-1706, Placebo (NNC9204-1706)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 9, 2026, 5:22 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (New Use) Weight Loss Study

NCT01272752
View directory record Official record
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial

NCT03640286
View directory record Official record
Conditions
Obesity
Interventions
VeSTAL
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
22 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
La Jolla, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fructose-Induced Palmitate Synthesis in Overweight Subjects

NCT00535535
View directory record Official record
Conditions
Elevated Triglycerides, Diabetes, Cardiovascular Disease
Interventions
Fructose, Fructose and Glucose
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

NCT00537420
View directory record Official record
Conditions
Obesity
Interventions
Nasal Placebo, Placebo Capsule, PYY3-36, Sibutramine
Drug
Lead sponsor
Nastech Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss

NCT00779519
View directory record Official record
Conditions
Obesity
Interventions
TTP435, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

NCT00331175
View directory record Official record
Conditions
Obesity
Interventions
Peptide YY3-36
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2006 · Synced Sep 9, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

NCT01235741
View directory record Official record
Conditions
Obesity
Interventions
Pramlintide+Metreleptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Greenbrae, California • La Jolla, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 9, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

NCT07282743
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3, GL0034 Dose Level 4, GL0034 Dose Level 5, GL0034 Dose Level 6, Placebo
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Hialeah Gardens, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition

NCT01251887
View directory record Official record
Conditions
Weight Gain, Healthy Subjects, Obesity, Women
Interventions
Linoleic Acid, Docosahexaenoic Acid, Eicosapentaenoic Acid
Dietary Supplement
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

NCT00819234
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Pramlintide and Metreleptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arkansas • Santa Rosa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

NCT04994769
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Epitomee Capsule
Device
Lead sponsor
Epitomee medical
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 9, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

NCT03414736
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 9, 2026, 5:22 AM EDT